PMC:7534795 / 20781-21009 JSONTXT

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T37131","span":{"begin":110,"end":111},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"}],"text":".30–0.77) than those with CRP \u003c15 mg/dL HR 0.92 (95% CI 0.57–1.48) • Tocilizumab treatment is associated with a lower rate of mortality, particularly in those with enhanced inflammatory state\n• Double blind RCT recently complete"}

{"project":"LitCovid-PubTator","denotations":[{"id":"658","span":{"begin":26,"end":29},"obj":"Gene"},{"id":"686","span":{"begin":126,"end":135},"obj":"Disease"}],"attributes":[{"id":"A658","pred":"tao:has_database_id","subj":"658","obj":"Gene:1401"},{"id":"A686","pred":"tao:has_database_id","subj":"686","obj":"MESH:D003643"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":".30–0.77) than those with CRP \u003c15 mg/dL HR 0.92 (95% CI 0.57–1.48) • Tocilizumab treatment is associated with a lower rate of mortality, particularly in those with enhanced inflammatory state\n• Double blind RCT recently complete"}